AIC. Dynavax.

Barbara, Bohle

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2003

Data sources: Europe PubMed Central

AIC. Dynavax.

descriptionPublicationkeyboard_double_arrow_right Article 08 Sep 2003 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 4 (issn: 1472-4472,

Copyright policy )

Authors: Barbara, Bohle;

pmid: 12833657

AIC. Dynavax.

- Summary
- Subjects
- Metrics

Abstract

Dynavax is developing Amb a 1 immunostimulatory oligodeoxynucleotide-conjugate (AIC) as a potential immunotherapy for ragweed-induced seasonal allergy. By May 2001, phase II/III trials were underway in Canada and the US, and by March 2002, phase II trials were underway in France. In October 2002, Dynavax expected to commence a phase III trial in 2003.

Related Organizations

University of Vienna
Austria

Keywords

Anti-Allergic Agents, Animals, Humans, Rhinitis, Allergic, Seasonal, Technology, Pharmaceutical, Allergens, Ambrosia, Antigens, Plant, Plant Proteins

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average